A Phase 2a Study to Assess Safety, Daily Symptoms, PK, and Biomarkers of YPL-001 in COPD Patients

ClinicalTrials.gov ID: NCT02272634

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT02272634. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 13, 2026, 1:09 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-Blind, Placebo Controlled, Multicenter 2a Study to Assess Safety, Daily Respiratory Symptoms, PK, and Biomarker Variations After Administration of Either YPL-001, or Placebo in Patients With Moderate-to-Severe COPD.

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a Phase 2a, proof-of-concept, multicenter, randomized, double-blind, double dummy, 3-treatment, parallel study, with low and high YPL 001 doses (low dose and high dose twice daily \[BID\]) and a placebo control in moderate to severe Chronic Obstructive Pulmonary Disease (COPD) patients.

Study identification

NCT ID: NCT02272634
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: Yungjin Pharm. Co., Ltd.; Industry
Enrollment: 61 participants

Conditions and interventions

Conditions

Chronic Obstructive Pulmonary Disease

Interventions

Drug

Eligibility (public fields only)

Age range: 30 Years to 85 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jun 4, 2015 (Actual)
Primary completion: Nov 8, 2017 (Actual)
Completion: Nov 8, 2017 (Actual)
Last update posted: Jul 14, 2023

2015 – 2017

United States locations

U.S. sites: 4
U.S. states: 4
U.S. cities: 4

Facility	City	State	ZIP	Site status
UAB Lung Health Center	Birmingham	Alabama	35249	—
Florida Pulmonary Research Institute, LLC	Winter Park	Florida	32789	—
Aventiv Research Inc.	Columbus	Ohio	43213	—
Temple Lung Center, Temple University Hospital	Philadelphia	Pennsylvania	191140	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT02272634, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jul 14, 2023 · Synced Nov 13, 2026